Essential thrombocythemia (ET), a myeloproliferative neoplasm frequently driven by JAK2 V617F mutations, results in thrombocytosis and hypercoagulability, elevating the risk of bleeding and thrombotic events including ischemic stroke. This evidence concerns the gene JAK2 and myeloproliferative neoplasm.